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A B S T R A C T
Background
Cataract formation or acceleration can occur after intraocular surgery, especially following vitrectomy, a surgical technique for removing
the vitreous which is used in the treatment of disorders that affect the posterior segment of the eye. The underlying problem that led
to vitrectomy may limit the benefit from cataract surgery.
Objectives
The objective of this review was to evaluate the effectiveness and safety of surgery for post-vitrectomy cataract with respect to visual
acuity, quality of life, and other outcomes.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 4),
Ovid MEDLINE, Ovid MEDLINE in-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily Update, Ovid OLDMED-
LINE (January 1946 to May 2013), EMBASE (January 1980 to May 2013, Latin American and Caribbean Health Sciences Literature
Database (LILACS) (January 1982 toMay 2013), PubMed (January 1946 toMay 2013), themetaRegister of Controlled Trials (mRCT)
(www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrial.gov) and the WHO International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 22 May 2013.
Selection criteria
We planned to include randomized and quasi-randomized controlled trials comparing cataract surgery with no surgery in adult patients
who developed cataract following vitrectomy.
Data collection and analysis
Two authors screened the search results independently according to the standard methodological procedures expected by The Cochrane
Collaboration.
Main results
We found no randomized or quasi-randomized controlled trials comparing cataract surgery with no cataract surgery for patients who
developed cataracts following vitrectomy surgery.
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Authors’ conclusions
There is no evidence from randomized or quasi-randomized controlled trials on which to base clinical recommendations for surgery for
post-vitrectomy cataract. There is a clear need for randomized controlled trials to address this evidence gap. Such trials should stratify
participants by their age, the retinal disorder leading to vitrectomy, and the status of the underlying disease process in the contralateral
eye. Outcomes assessed in such trials may include gain of vision on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale,
quality of life, and adverse events such as posterior capsular rupture. Both short-term (six-month) and long-term (one-year or two-
year) outcomes should be examined.
P L A I N L A N G U A G E S U M M A R Y
Surgery to remove cataracts after vitrectomy
Review question
We reviewed the evidence about the effect of surgery to remove cataracts (cloudy lens in front of the eye) in people who develop cataracts
after vitrectomy, a surgery to remove the vitreous (the clear gel) in the center of the eye.
Background
Vitrectomy, a procedure performed for disorders that affect the back part of the eye, can result in the formation or acceleration of
cataract. The underlying problem that led to vitrectomy may limit the benefits from cataract surgery.
Results
We found no randomized controlled trials (trials in which participants are randomly assigned to one treatment group or another) that
evaluated the benefits or risks (or both) of cataract surgery following vitrectomy. Since cataract surgery may lead to loss of vision due
to worsening or recurrence of the condition that prompted the vitrectomy, its role in these patients remains uncertain. Future trials to
address this review question should separate participants by age, the disorder leading to vitrectomy, and the status of the underlying
disease process in the opposite eye. Outcomes relevant to patients such as improvement of vision and quality of life, and harms should
be examined both in the short term (six months after surgery) and in the long term (one to two years after surgery).
B A C K G R O U N D
Description of the condition
Cataract, an opacification of the crystalline lens in the eye, can
be caused by many factors including the natural aging process,
metabolic abnormalities, nutritional disorders, chronic ocular in-
flammation, and trauma. The three types of cataract are classified
according to the location of the opacity: cortical, nuclear sclerosis,
and posterior subcapsular. Cataract formation or acceleration also
can occur after intraocular surgery, especially following vitrectomy,
a surgical technique for removing the vitreous that is used in the
treatment of disorders that affect the posterior segment of the eye.
Vitrectomy causes progression of nuclear sclerotic cataracts.
Vitrectomy was first developed byMachemer in 1971 (Machemer
1971). It is a microsurgical technique in which specialized instru-
ments and techniques are used to gain access to the vitreous cavity
and retina. During vitrectomy surgery, three small incisions, each
approximately 1.4 mm in length, are made in the eye in order to
place instruments: a vitreous cutter, a fiberoptic light source to
illuminate the inside of the eye, and an infusion cannula to main-
tain proper intraocular pressure during the surgery. During the
past 40 years, advances in surgical technique and instrumentation
have made vitrectomy a common surgical procedure for posterior
segment disorders. Vitrectomy is indicated for numerous ocular
conditions including vitreous loss in cataract surgery, subluxation
of the lens,malignant glaucoma, dense pupillarymembranes, non-
clearing vitreous hemorrhage due to diabetic retinopathy or vein
occlusions, retinal detachment, macular hole, macular pucker, vit-
reo-macular traction, and endophthalmitis.
Although vitrectomy has revolutionized the treatment of posterior
segment disorders and improved visual outcomes in patients with
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retinal diseases requiring surgical intervention, vitrectomy also is
associated with co-morbidities that may compromise visual acuity
such as retinal detachment, corneal decompensation, and cataract
formation or progression in phakic eyes (Benson 1988). The type
of cataract that forms or accelerates after vitrectomy is nuclear
sclerotic cataract. Cataract formation or progression is believed to
be the most common complication associated with vitrectomy. In
fact, in many eyes undergoing vitrectomy, the lens is removed at
the same time. Often, the nuclear sclerotic cataracts that develop
after vitrectomy limit visual acuity outcomes to a degree thatwould
result in surgical removal of the lens in an otherwise ’normal’ eye.
The exact pathogenesis of cataract formation or acceleration after
vitrectomy is unknown. Older studies have suggested that light
toxicity, oxidation of lens proteins, use of intraocular gas, and
length of operative time may be causative factors (Cherfan 1991;
de Bustros 1988; Ogura 1991). Newer research suggests that vit-
rectomy surgery increases oxygen tension within the eye; oxygen
exposure has been linkedwith progressive nuclear sclerotic cataract
formation (Holekamp 2005; Palmquist 1988).
Epidemiology
Although cataract progression is common after vitrectomy, only
a few prospective studies have evaluated this occurrence. Do and
Hawkins performed a review (unpublished) of the pertinent lit-
erature in the PubMed database published from 1966 through
2005. A total of 51 studies were found. The majority of published
studies on cataract progression after vitrectomy were retrospective
analyses. The reported incidence of cataract was highly variable,
from 6% to 100% of cases, depending upon the condition that
prompted vitrectomy, duration of follow-up, and themethod used
to monitor development of cataract. These retrospective studies
are limited by the non-uniformity of the lens grading system used
or the absence of a description of the lens grading system in the
published report.
The Vitrectomy for Macular Hole Study, a randomized controlled
trial that evaluated vitrectomy for the treatment of macular holes,
retrospectively examined the incidence of cataract development
among 74 eyes of patients that participated in the study (Cheng
2001). Investigators used a scoring system similar to the Lens
Opacities Classification System II, which contains five grading cat-
egories for nuclear and posterior subcapsular opacities. Although
duration of surgery did not increase the risk for cataract progres-
sion, vitrectomy itself was a risk factor for cataract acceleration; 60/
74 (81%) eyes in the surgery cohort had nuclear sclerotic cataract
progression at six months of follow-up, compared to only 13/74
(18%) fellow eyes in the control group. By two years, 100% of eyes
in the surgery cohort had cataract progression, compared to 8%
of control eyes. Similarly, Cherfan and colleagues retrospectively
reviewed 100 eyes after vitrectomy for idiopathic macular pucker
(Cherfan 1991). After an average follow-up of 29 months (range
six to 99 months), 80/100 (80%) eyes in the vitrectomy group and
only 24/100 (24%) fellow eyes had developed a visually significant
nuclear sclerotic cataract or had undergone cataract extraction.
During the late 1990s, the Submacular Surgery Trials (SST) were
initiated to evaluate surgical removal of subfoveal choroidal neo-
vascularization (CNV) compared with observation in patients
with age-relatedmacular degeneration (AMD) (SSTGroupN and
Group B), ocular histoplasmosis syndrome (OHS) (SST Group
H), and idiopathicCNV (SSTGroupH) (SST 2004a; SST2004b;
SST 2004c). In these three randomized controlled trials, visually
significant cataract was defined as either cataract surgery or lens
opacity reported by the SST ophthalmologist to be sufficient to
reduce visual acuity by two or more lines in a normal eye. Among
the AMD participants in the SSTGroup N study, 80% of eyes as-
signed to vitrectomy and surgical removal of their subfoveal CNV
developed visually significant cataracts at two years of follow-up.
Sixty per cent of eyes had undergone cataract surgery by their
last follow-up examination two to four years after enrollment.
Among the OHS participants in the SST Group H study, 39% of
eyes assigned to vitrectomy developed visually significant cataracts,
among which 24% underwent cataract removal. The difference
between eyes with AMD and eyes with OHS developing post-
vitrectomy cataract is likely due to the median age of the patients.
Patients under the age of 50 years are less likely to develop post-
surgical accelerated nuclear sclerosis (Melberg 1995). Data from
the SST provide the largest and most complete follow-up of eyes
undergoing vitrectomy that are at high risk for developing visually
significant post-surgical nuclear sclerotic cataracts.
Presentation and diagnosis
Patients who develop post-vitrectomy cataract present with de-
creased visual acuity despite anatomic or functional success (or
both) of the vitrectomy surgery. Individuals who have undergone
vitrectomy may have lower levels of baseline (pre-cataract) visual
acuity due to the underlying nature of their retinal pathology;
therefore patients with post-vitrectomy cataract are more likely
to present with poorer vision than individuals with typical senile
cataracts. Diagnosis is made with ocular examination using slit-
lamp biomicroscopy.
Description of the intervention
Cataract surgery, typically using phacoemulsification and intraoc-
ular lens implantation, is commonly recommended for individ-
uals with visually significant lens opacities. Two features of post-
vitrectomy nuclear sclerosis make affected lenses especially chal-
lenging for cataract surgeons to remove. The nucleus tends to be
harder than in age-related nuclear sclerosis, requiring longer pha-
coemulsification time during the procedure. Also, the absence of
vitreous in the posterior segment allows for more mobility of the
posterior capsule, increasing the risk of capsular rupture. Thus,
surgery for post-vitrectomy nuclear sclerotic cataract may have a
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higher incidence of complications, although evidence from com-
parative studies is lacking (Ahfat 2003; Biro 2002).
How the intervention might work
Patients who develop cataract after vitrectomy may undergo
cataract extraction; however, visual acuity and other outcomes af-
ter cataract surgery may be poor due to the underlying retinal
disorder. Most patients who have vitrectomy surgery have seri-
ous underlying problems, as indicated by the reasons for vitrec-
tomy. Furthermore, eyes with post-vitrectomy cataract are at risk
of complications that affect all eyes that undergo cataract surgery
such as endophthalmitis, cystoid macular edema, etc. Thus, vi-
sion is often already impaired before cataract surgery and may re-
main impaired after cataract surgery. Although cataract surgery in
a normal eye typically improves vision, the visual prognosis after
surgery for post-vitrectomy cataract is uncertain. It likely depends
on the success of treatment for the retinal disorder and avoidance
of complications during cataract surgery.
Why it is important to do this review
The incidence of cataract formation after vitrectomy varies widely
and has been reported to be between 6% and 100%. The majority
of published studies confirm that a high rate of cataract formation
occurs, but few data are available on visual acuity outcomes after
cataract removal. The retinal problem that led to vitrectomy may
progress or recur. However, peer-reviewed data on outcomes after
surgery for post-vitrectomy cataract are scarce. Even in situations
in which cataract formation is not due to vitrectomy, visual im-
pairment can still exist despite cataract extraction. The Los Ange-
les Latino Eye Study (Barañano 2007) published visual acuity out-
comes after cataract extraction in adult Latinos and reported that
41% of eyes had visual impairment (defined as a best-corrected
visual acuity of 20/40 Snellen equivalent or less). Age-related mac-
ular degeneration and diabetic retinopathy accounted for approxi-
mately 57% of retinal pathology after cataract extraction. In addi-
tion, in eyes that have undergone vitrectomy surgery the absence
of vitreous in the posterior segment allows for moremobility of the
posterior capsule, increasing the risk of capsular rupture. Surgery
for post-vitrectomy nuclear sclerotic cataract may have a higher
incidence of complications. A systematic review of outcomes from
controlled clinical trials would provide information for adequate
counseling of patients and for guiding ophthalmologists’ recom-
mendations.
O B J E C T I V E S
The objective of this review was to evaluate the effectiveness and
safety of surgery for post-vitrectomy cataract with respect to visual
acuity, quality of life, and other outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include both randomized and quasi-randomized
controlled trials in this review. We considered quasi-randomized
trials to be trials that had adopted a method of allocation intended
to allocate patients in a random fashion but were not strictly ran-
dom. Examples include allocation by date of birth, social security
number, etc.We were to include trials with at least six months’ fol-
low-up to allow for reporting of early adverse effects, even though
we planned our primary analyses to focus on outcomes at the end
of one year of follow-up.
Types of participants
We planned to include trials that enrolled adult participants (age
18 years and over) with cataract that had developed after vitrec-
tomy for any indication except for trauma. However, we planned
not to exclude trials that included both adult patients who had
post-traumatic vitrectomy and patients who had other indications
for vitrectomy, except when outcomes were reported separately by
indication. We planned to exclude trials that included only trauma
cases, because these patients typically are younger and the patho-
genesis of cataract formation is different.
Types of interventions
We planned to include trials that compared cataract surgery (of
any type) with no surgery in such patients.
Types of outcome measures
Primary outcomes
Visual acuity improvement after cataract surgery of at least three
letters on a logMAR chart, one line on the Snellen chart, or equiv-
alent changes on other scales. While we planned to analyze the
outcomes at one year, two years, and at longer time points of fol-
low-up as available from included studies, our primary analysis
was to focus on one-year follow-up.
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Secondary outcomes
1. Quality of life measured by a validated scale.
2. Contrast sensitivity: improvement of at least one level,
regardless of the manner in which it was measured in included
trials.
3. Progression of the condition that was the original
indication for vitrectomy in patients with diabetic retinopathy
(DR) and age-related macular degeneration (AMD) as defined
by standard grading scales such as the Diabetic Retinopathy
Scale for DR (ETDRS 1991) and the International Scale for
AMD (Bird 1995).
Adverse outcomes
Specific adverse effects of interest included:
• cystoid macular edema;
• intraocular lens-related complications, including
dislocation, difficulty in placing the lens;
• capsular opacification;
• retinal detachment (new or recurrent).
We also planned to summarize all other adverse effects reported
in included studies.
Economic outcomes
We planned to tabulate or summarize data on the costs of proce-
dures, consequences of complications, and any cost-effectiveness
data reported in included studies in a narrative fashion.
Search methods for identification of studies
Electronic searches
In 2013, we revised the searches of electronic databases from
the 2011 update. We searched PubMed and the Interna-
tional Clinical Trials Registry Platform, which had not origi-
nally been searched. We searched the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) (which contains the
Cochrane Eyes and Vision Group Trials Register) 2013, Issue
4, part of The Cochrane Library. www.thecochranelibrary.com
(accessed 22 May 2013), Ovid MEDLINE, Ovid MEDLINE
In-Process and Other Non-Indexed Citations, Ovid MEDLINE
Daily Update, Ovid OLDMEDLINE (January 1946 to August
2013), EMBASE (January 1980 to May 2013), Latin American
and Caribbean Health Sciences Literature Database (LILACS)
(January 1982 to May 2013), the metaRegister of Controlled
Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (
www.clinicaltrial.gov), the WHO International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/search/en) and
PubMed (January 1956 to May 2013). We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 22 May 2013.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), mRCT (Appendix 5), ClinicalTrials.gov
(Appendix 6), ICTRP (Appendix 7) and PubMed (Appendix 8).
The UK Clinical Research Network Portfolio Database and the
Australian New Zealand Clinical Trials Registry are no longer be-
ing searched for this review.
Searching other resources
We planned to search the reference lists of included studies and
the Science Citation Index - Expanded database to identify any
additional trials. We did not search any conference proceedings
specifically for the purpose of this review.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and abstracts
of all records identified in the electronic and manual searches. We
labeled each record as ’A - include’, ’B - unsure’, or ’C - exclude’.
Two authors then screened the full reports of records labeled ’B -
unsure’; we relabeled each record as ’A - include’ or ’C - exclude’
based on consensus after review. We listed studies reported in
records labeled ’C - exclude’ after full-text review in the table of
excluded studies with reasons for exclusion. We planned to assess
methodological quality for studies labeled as ’A - include’; however,
we did not identify any study labeled as ’A - include’ by either of
the two review authors.
We found no trials eligible for inclusion in either the original
review or the updated review. The methods described below
will be applicable to future updates of the review when trials
eligible for inclusion have been conducted and reported.
Data extraction and management
Two review authors will independently extract data on basic char-
acteristics of each study (including details of study design, charac-
teristics of participants, interventions, and comparators) and the
primary and secondary outcomes onto data collection forms devel-
oped in collaboration with the Cochrane Eyes and Vision Group.
We will resolve discrepancies by discussion. We will contact au-
thors of included studies for missing data. One review author will
enter all data into RevMan 5.2 (RevMan 2013) and another au-
thor will verify the data.
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Assessment of risk of bias in included studies
Two review authors, working independently, will assess the in-
cluded studies for sources of systematic bias according to the guide-
lines in Chapter 8 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011a).We will evaluate studies for
the following criteria: method of randomization, allocation con-
cealment (selection bias), masking of outcome assessment, com-
pleteness of outcome data and intention-to-treat analysis (attrition
bias), and other potential sources of bias including source of trial
funding. We will not assess masking of investigators as the inter-
ventions to be compared preclude such efforts. Though an artifi-
cial lens placed in the eyes of patients in the intervention group
may be recognized by the anatomic outcome assessor, visual acu-
ity testing may have been performed by someone not responsible
for examining the eye. Also, quality of life data may have been
collected by some method that preserves masking of intervention
or outcome assessment, or both. We will judge each criterion as
either ’low risk of bias’, ’high risk of bias’, or ’unclear risk of bias’.
We will use information in the Cochrane Handbook for Systematic
Reviews of Interventions to guide our judgment for each criterion.
Wewill contact authors of studies labeled ’unsure’ for clarification.
Differences between the two review authors will be resolved by
discussion.
Measures of treatment effect
We will calculate a summary risk ratio for dichotomous outcomes
(visual acuity improvement, progression of the condition that was
the original indication for vitrectomy, and adverse events). We will
calculate the mean difference for continuous outcomes (quality of
life, cost-effectiveness, and contrast sensitivity).
Unit of analysis issues
The unit of analysis will be the eye for vision-related outcomes
(visual acuity, contrast sensitivity, progression, and adverse events).
For quality of life and economic outcomes, the unit of analysis
will be the person.
Dealing with missing data
We will attempt to contact the investigators of included trials for
any missing data. If the investigators do not respond within four
weeks, we will extract available data from the published report.
We will refer to the guidelines in Chapter 16 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b)
for handling missing data.
Assessment of heterogeneity
We will examine the design and clinical heterogeneity among in-
cluded studies by carefully analyzing their characteristics. We also
will examine the degree of overlap in the confidence intervals of
the studies. If there is poor overlap, this will be taken to indicate
the presence of statistical heterogeneity. We will test for statistical
heterogeneity formally using the Chi2 test. We also will use the I
2 statistic value to determine the proportion of variation due to
heterogeneity among studies, and will consider an I2 value greater
than 50% to indicate substantial statistical heterogeneity.
Assessment of reporting biases
We will examine a funnel plot to identify any evidence of publi-
cation bias when a sufficient number of studies are included, i.e.,
10 or more.
Data synthesis
If no significant heterogeneity is detected, either statistically or if
there is a small number of trials in the analysis (three or fewer),
we will use a fixed-effect model. If the number of trials is greater
than three and no heterogeneity has been detected, we will use a
random-effects model.
If significant heterogeneity has been detected, we will not combine
results to produce a single summary measure. In this case, we will
describe the forest plot in the results section of the review.
Subgroup analysis and investigation of heterogeneity
We will investigate heterogeneity, if present, through subgroup
analyses. If sufficient data are available, we will conduct subgroup
analyses based on the agents used to fill the vitreous space after
vitrectomy, e.g., air, different gases, and by different indications
for vitrectomy.
Sensitivity analysis
We will conduct sensitivity analyses to determine the impact of
exclusion of studies of lower methodological quality, including
quasi-randomized trials, and exclusion of industry-funded studies
and unpublished studies.
R E S U L T S
Description of studies
Results of the search
The original electronic searches retrieved a total of 1949 refer-
ences and 29 additional records from clinical trials registers. After
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independent review of the titles and abstracts by two review au-
thors, we retrieved 36 full-text articles. We found no randomized
or quasi-randomized trials eligible for inclusion in the review.
An updated search was done in April 2011; we retrieved 785 ref-
erences and 18 additional records from clinical trials registers. We
assessed the records but none were eligible for inclusion in the
review.
The most recent updated search conducted in May 2013 yielded
1009 references and 120 additional records from clinical trials
registers. We assessed the records but none were eligible for in-
clusion in the review (Figure 1). During the process of the most
recent update, we also re-assessed the eligibility for all previously
excluded studies, and removed 22 out of 36 references from the
list by reviewing titles and abstracts. All of the 22 references were
either non-human study or non randomized controlled trials. We
still kept the reasons for exclusion for the remaining 14 references
for 10 studies in the ’Characteristics of excluded studies’ table.
Figure 1. Study flow diagram.
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Included studies
Wedid not identify any studies eligible for inclusion in this review.
Excluded studies
Review of the full-text articles did not identify any studies that are
relevant to the objective of this systematic review.
Risk of bias in included studies
We found no trials eligible for inclusion in the review for assess-
ment of risk of bias.
Effects of interventions
We found no information on effects of interventions from trials
eligible for inclusion in the review.
D I S C U S S I O N
The majority of the published literature on this subject is limited
to retrospective case reports or non-randomized prospective case
series (Ahfat 2003). Any attempt to draw conclusions from these
non-randomized studies would be misleading. In addition, there
is no reliable method to identify all observational studies on this
topic; therefore data collection is likely to be incomplete. Thus,
our protocol specifically stated that we were interested in out-
comes based on randomized or quasi-randomized clinical trials,
not observational studies. This dearth of information on surgery
for post-vitrectomy cataract indicates that information on this
topic is needed, as thousands of patients undergo vitrectomy each
year and are at risk of development of cataract and cataract surgery.
Documentation of both the risks and benefits of surgery for post-
vitrectomy cataract is needed to inform patient counseling and
clinical recommendations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In the absence of data fromcontrolled trials, ophthalmologists have
no reliable evidence to use when counseling patients regarding the
risks and benefits of surgery for post-vitrectomy cataract, and no
basis for recommendations for or against cataract surgery or when
to intervene surgically. It is possible that some of the complications
of surgery for post-vitrectomy cataract could be reduced if surgery
were known to be beneficial and to be beneficial if performed
at an early stage of development of nuclear sclerosis. Data from
retrospective studies are inadequate for these purposes.
Implications for research
There is a clear need for well-designed randomized controlled tri-
als to evaluate the benefits and risks of surgery for cataracts that
develop following vitrectomy.We recommend that randomization
in such trials be stratified by patients’ age, retinal disorder leading
to vitrectomy, and status of the pathologic process in the contralat-
eral eye. Because patients who undergo vitrectomy already have
reduced vision due to the underlying condition that prompted vit-
rectomy, relevant outcomes such as quality of life should be con-
sidered in addition to visual acuity and other clinical measures of
vision. We recommend that restoration or gain of eight or more
letters vision on the ETDRS scale with cataract surgery would be a
reasonable expectation in this patient population. Analyses should
include both short-term (six months) and long-term (one-year to
two-year) outcomes. Data on adverse outcomes, including com-
plications of surgery such as posterior capsular rupture, should be
documented in future trials.
However, there are ethical difficulties in conducting a random-
ized trial of surgery for post-vitrectomy cataract. Observation of
progression of post-vitrectomy cataract may not be considered an
ethical alternative. In certain patient populations, such as those
with significant central vision loss due to macular scars, observa-
tion of post-vitrectomy cataract may be ethical, and conducting
a randomized controlled trial to determine if cataract surgery im-
proves quality of lifemay be a reasonable option. One possible trial
design would be to enroll patients over the age of 50 years who
are scheduled for vitrectomy, who do not have visually significant
cataract in the study eye, and who have visual acuity better than
20/40 in the fellow eye in a two-stage RCT. The initial randomiza-
tion would be between vitrectomy alone and vitrectomy plus lens
removal. Any cataract surgery in the fellow eye would be deferred
for at least six months. At six months, study eyes in the deferred
group in which visually significant cataract had developed would
then be randomized to cataract surgery or deferment for another
six months. At the end of the second six-month period, all patients
with visually significant cataract in the study eye could be offered
surgery. This design would permit evaluation of:
• time to development or progression of cataract in the initial
vitrectomy only arm;
• time to progression or recurrence of the underlying retinal
problem that led to vitrectomy in the two initial treatment arms;
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• comparison of quality of life between the two arms of the
original randomization; and
• (with the second randomization) comparison of the above
outcomes with and without cataract surgery.
This design would take account of the large number of patients
who have lens surgery at the time of vitrectomy and might sup-
port that practice or suggest that it was desirable only in selected
subgroups of patients, as long as the fellow eye had useful vision.
Concerns about surgical complications, prognosis for recovery of
visual acuity, and uncertainty regarding progression of underly-
ing retinal disorder, are important considerations in establishing
equipoise necessary for randomization. Further, insufficient infor-
mation on outcomes important to patients, such as vision-related
quality of life, indicates an inability to reasonably assess risks and
benefits of surgery for post-vitrectomy cataract.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmadieh 2005 RCT, not post-vitrectomy patients
Asaria 2001 RCT, post-vitrectomy patients, not for cataract surgery
Batman 1999 RCT, not post-vitrectomy patients, not cataract surgery
Blankenship 1980 RCT, not post-vitrectomy patients, not for cataract surgery
DRVS 1985 RCT or CCT, not post-vitrectomy patients, not cataract surgery
Ehud 1988 RCT, not post-vitrectomy patients, not for cataract surgery
Ezra 2004 RCT, not post-vitrectomy patients, not for cataract surgery
Freeman 1997 RCT, not post-vitrectomy patients, not for cataract surgery
Haimann 1984 RCT, not post-vitrectomy patients, not for cataract surgery
Silicone Study 1992 RCT for post-vitrectomy patients, not for cataract surgery
CCT: controlled clinical trial
RCT: randomized controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Vitrectomy] explode all trees
#2 MeSH descriptor: [Vitreoretinal Surgery] explode all trees
#3 (vitrectom* or post-vitrectom* or postvitrectom*)
#4 (vitreous surg* or vitreous resection* or vitreoretinal surg*)
#5 #1 or #3 or #4
#6 MeSH descriptor: [Cataract] explode all trees
#7 MeSH descriptor: [Cataract Extraction] explode all trees
#8 MeSH descriptor: [Capsulorhexis] explode all trees
#9 MeSH descriptor: [Phacoemulsification] explode all trees
#10 cataract*
#11 lens*
#12 (phakectom* or zonulolys* or catarectom*)
#13 (pha?oemulsif* or pha?o or Capsulor?hexis)
#14 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 #5 and #14
Appendix 2. MEDLINE (OvidSP) search strategy
1. Randomized Controlled Trial.pt.
2. Controlled Clinical Trial.pt.
3. (randomized or randomised).ab,ti.
4. placebo.ab,ti.
5. drug therapy.fs.
6. randomly.ab,ti.
7. trial.ab,ti.
8. groups.ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Vitrectomy/
13. exp Vitreoretinal Surgery/
14. (vitrectom* or post-vitrectom* or postvitrectom*).tw.
15. (vitreous surg* or vitreous resection* or vitreoretinal surg*).tw.
16. 12 or 14
17. exp Cataract/
18. exp Cataract Extraction/
19. exp Capsulorhexis/
20. exp Phacoemulsification/
21. cataract*.tw.
22. lens*.tw.
23. (Phakectom* or Zonulolys* or catarectom*).tw.
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24. (pha?oemulsif* or pha#o or Capsulor?hexis).tw.
25. or/17-24
26. 16 and 25
27. 11 and 26
Appendix 3. EMBASE.com search strategy
#1 ’randomized controlled trial’/exp
#2 ’randomization’/exp
#3 ’double blind procedure’/exp
#4 ’single blind procedure’/exp
#5 random*:ab,ti
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 ’animal’/exp OR ’animal experiment’/exp
#8 ’human’/exp
#9 #7 AND #8
#10 #7 NOT #9
#11 #6 NOT #10
#12 ’clinical trial’/exp
#13 (clin* NEAR/3 trial*):ab,ti
#14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*)):ab,ti
#15 ’placebo’/exp
#16 placebo*:ab,ti
#17 random*:ab,ti
#18 ’experimental design’/exp
#19 ’crossover procedure’/exp
#20 ’control group’/exp
#21 ’latin square design’/exp
#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #22 NOT #10
#24 #23 NOT #11
#25 ’comparative study’/exp
#26 ’evaluation’/exp
#27 ’prospective study’/exp
#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti
#29 #25 OR #26 OR #27 OR #28
#30 #29 NOT #10
#31 #30 NOT (#11 OR #23)
#32 #11 OR #24 OR #31
#33 ’vitrectomy’/exp
#34 ’vitreoretinal surgery’/de
#35 vitrectom*:ab,ti OR postvitrectom*:ab,ti
#36 (vitreous NEAR/1 surg*):ab,ti OR (vitreous NEAR/1 resection*):ab,ti OR (vitreoretinal NEAR/1 surg*):ab,ti
#37 #33 OR #34 OR #35 OR #36
#38 ’cataract’/exp
#39 ’cataract extraction’/exp
#40 ’capsulorhexis’/exp
#41 ’phacoemulsification’/exp
#42 cataract*:ab,ti
#43 lens*:ab,ti
#44 phakectom*:ab,ti OR zonulolys*:ab,ti OR catarectom*:ab,ti
#45 pha?oemulsif* OR pha?o OR capsulor?hexis
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#46 #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45
#47 #32 AND #37 AND #46
Appendix 4. LILACS search strategy
(Vitrectom$ OR post-vitrectom$ OR postvitrectom$ OR “vitreous surgery” OR “vitreous surgeries” OR “vitreous resection” OR “vit-
reoretinal surgery” OR “vitreoretinal surgeries” OR MH:E04.540.960$) AND (Cataract$ OR Catarata$ OR MH:C11.510.245$ OR
MH:E04.540.825.249$ ORMH:E04.943.875$ OR lens$ ORCapsulorhexis ORCapsulorrexis OR Capsulorrexe ORCapsulorrhexis
OR Phacoemulsif$ OR Facoemulsif$ OR Phakectom$ OR Zonulolys$ OR catarectom$ OR Phakoemulsif$)
Appendix 5. metaRegister of Controlled Trials search strategy
cataract and vitrectomy
Appendix 6. ClinicalTrials.gov search strategy
cataract AND vitrectomy
Appendix 7. ICTRP search strategy
cataract AND vitrectomy
Appendix 8. PubMed search strategy
#1 ((randomized controlled trial[pt])OR (controlled clinical trial[pt])OR (randomised[tiab]OR randomized[tiab])OR (placebo[tiab])
OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT (animals[mh] NOT humans[mh])
#2 (vitrectom*[tiab] OR post-vitrectom*[tiab] OR postvitrectom*[tiab]) NOTMedline[sb]
#3 (“vitreous surgery”[tiab]OR“vitreous surgeries”[tiab]ORvitreous resection*[tiab]OR“vitreoretinal surgery”[tiab]OR“vitreoretinal
surgery”[tiab]) NOTMedline[sb]
#4 (#2 OR #3)
#5 (cataract*[tiab]) NOTMedline[sb]
#6 (lens*[tiab]) NOTMedline[sb]
#7 (Phakectom*[tiab] OR Zonulolys*[tiab] OR catarectom*[tiab]) NOT Medline[sb]
#8 (phaco*[tiab] OR phako*[tiab]OR Capsulorhexis[tiab] OR Capsulorrhexis[tiab) NOTMedline[sb]
#9 (#5 OR #6 OR #7 OR #8)
#8 (#1 AND #4 AND #9)
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